Bioprinting Neural Systems to Model Central Nervous System Diseases

Qiu, Boning; Bessler, Nils; Figler, Kianti P.; Buchholz, Maj‐Britt; Rios, Anne C.; Malda, Jos; Levato, Riccardo; Caiazzo, Massimiliano

doi:10.1002/adfm.201910250

Cited by 48 publications

(45 citation statements)

References 249 publications

(316 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conventional SLA allows for higher resolution (<30 μm 248 ) but is associated with longer printing times (delivery rate ≈ 10 mm 3 min –1 5 ), due to the scanning of the laser across each layer. In DLP ( Figure 9 ), on the other hand, every pixel in each layer is projected in parallel onto the resin, allowing for faster fabrication rates (delivery rate ≈ 20 mm 3 min –1 5 , 248 , 249 ) in lithography-based bioprinting. 167 An advantage of light-based systems over extrusion approaches is the possibility to print structures directly into a volume and therefore even add and remove, via photo-cross-linking or photodegradation, 250 elements from an inner part of construct without altering the bulk of printed structure.…”

Section: Implications For Lithography-based Printing Technologiesmentioning

confidence: 99%

Printability and Shape Fidelity of Bioinks in 3D Bioprinting

et al. 2020

Self Cite

View full text Add to dashboard Cite

Three-dimensional bioprinting uses additive manufacturing techniques for the automated fabrication of hierarchically organized living constructs. The building blocks are often hydrogel-based bioinks, which need to be printed into structures with high shape fidelity to the intended computer-aided design. For optimal cell performance, relatively soft and printable inks are preferred, although these undergo significant deformation during the printing process, which may impair shape fidelity. While the concept of good or poor printability seems rather intuitive, its quantitative definition lacks consensus and depends on multiple rheological and chemical parameters of the ink. This review discusses qualitative and quantitative methodologies to evaluate printability of bioinks for extrusion- and lithography-based bioprinting. The physicochemical parameters influencing shape fidelity are discussed, together with their importance in establishing new models, predictive tools and printing methods that are deemed instrumental for the design of next-generation bioinks, and for reproducible comparison of their structural performance.

show abstract

Section: Implications For Lithography-based Printing Technologiesmentioning

confidence: 99%

Printability and Shape Fidelity of Bioinks in 3D Bioprinting

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The bioprinted construct captured the cell–cell and cell–environment interactions, which are key to modeling the overall tissue behavior in vivo and determining patient-specific differences. It is predicted that, once guided neurite outgrowth becomes feasible through 3D bioprinting, modeling specific neural networks could prove extremely useful for studying the specific effects of ND pathogenesis as well as for in vitro pharmacology aimed towards drug discovery [ 69 ].…”

Section: Prospect Of Human Pluripotent Stem Cellsmentioning

confidence: 99%

Induced Pluripotent Stem Cells for Treatment of Alzheimer’s and Parkinson’s Diseases

Yefroyev,

Jin

2022

Biomedicines

View full text Add to dashboard Cite

Neurodegenerative diseases are a group of debilitating pathologies in which neuronal tissue dies due to the buildup of neurotoxic plaques, resulting in detrimental effects on cognitive ability, motor control, and everyday function. Stem cell technology offers promise in addressing this problem on multiple fronts, but the conventional sourcing of pluripotent stem cells involves harvesting from aborted embryonic tissue, which comes with strong ethical and practical concerns. The keystone discovery of induced pluripotent stem cell (iPSC) technology provides an alternative and endless source, circumventing the unfavorable issues with embryonic stem cells, and yielding fundamental advantages. This review highlights iPSC technology, the pathophysiology of two major neurodegenerative diseases, Alzheimer’s and Parkinson’s, and then illustrates current state-of-the-art approaches towards the treatment of the diseases using iPSCs. The technologies discussed in the review emphasize in vitro therapeutic neural cell and organoid development for disease treatment, pathological modeling of neurodegenerative diseases, and 3D bioprinting as it applies to both.

show abstract

“…However, they still cannot properly demonstrate the physiological complexities of the human nervous system. Hence, these constraints highlight the need to seek efficient modeling methods instead of previous ones ( 85 , 86 ). Accordingly, multidisciplinary efforts were made to develop an appropriate modeling method that can mimic the biology of the human body systems with an eye toward different therapeutic purposes.…”

Section: Ooc As a Potential Strategy For Disease Modeling And Drug Discoverymentioning

confidence: 99%

Organ on a Chip: A Novel in vitro Biomimetic Strategy in Amyotrophic Lateral Sclerosis (ALS) Modeling

et al. 2022

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis is a pernicious neurodegenerative disorder that is associated with the progressive degeneration of motor neurons, the disruption of impulse transmission from motor neurons to muscle cells, and the development of mobility impairments. Clinically, muscle paralysis can spread to other parts of the body. Hence it may have adverse effects on swallowing, speaking, and even breathing, which serves as major problems facing these patients. According to the available evidence, no definite treatment has been found for amyotrophic lateral sclerosis (ALS) that results in a significant outcome, although some pharmacological and non-pharmacological treatments are currently applied that are accompanied by some positive effects. In other words, available therapies are only used to relieve symptoms without any significant treatment effects that highlight the importance of seeking more novel therapies. Unfortunately, the process of discovering new drugs with high therapeutic potential for ALS treatment is fraught with challenges. The lack of a broad view of the disease process from early to late-stage and insufficiency of preclinical studies for providing validated results prior to conducting clinical trials are other reasons for the ALS drug discovery failure. However, increasing the combined application of different fields of regenerative medicine, especially tissue engineering and stem cell therapy can be considered as a step forward to develop more novel technologies. For instance, organ on a chip is one of these technologies that can provide a platform to promote a comprehensive understanding of neuromuscular junction biology and screen candidate drugs for ALS in combination with pluripotent stem cells (PSCs). The structure of this technology is based on the use of essential components such as iPSC- derived motor neurons and iPSC-derived skeletal muscle cells on a single miniaturized chip for ALS modeling. Accordingly, an organ on a chip not only can mimic ALS complexities but also can be considered as a more cost-effective and time-saving disease modeling platform in comparison with others. Hence, it can be concluded that lab on a chip can make a major contribution as a biomimetic micro-physiological system in the treatment of neurodegenerative disorders such as ALS.

show abstract

Bioprinting Neural Systems to Model Central Nervous System Diseases

Cited by 48 publications

References 249 publications

Printability and Shape Fidelity of Bioinks in 3D Bioprinting

Printability and Shape Fidelity of Bioinks in 3D Bioprinting

Induced Pluripotent Stem Cells for Treatment of Alzheimer’s and Parkinson’s Diseases

Organ on a Chip: A Novel in vitro Biomimetic Strategy in Amyotrophic Lateral Sclerosis (ALS) Modeling

Contact Info

Product

Resources

About